Appropriate Number of Docetaxel Cycles in Castration-Resistant Prostate Cancer Patients Considering Peripheral Neuropathy and Oncological Control
- 1 January 2020
- journal article
- research article
- Published by S. Karger AG in Chemotherapy
- Vol. 65 (5-6), 119-124
- https://doi.org/10.1159/000510900
Abstract
Background: The number of cycles of docetaxel required for castration-resistant prostate cancer (CRPC) is unclear. This study estimated peripheral neuropathy (PN) incidence and the optimal number of treatment cycles in patients receiving docetaxel for CRPC. Patients and Methods: The study retrospectively reviewed 82 patients receiving docetaxel for CRPC at an institution between January 2005 and January 2017. Docetaxel (70 or 75 mg/m2) was administered every 3 weeks, and prednisone 5 mg or dexamethasone 0.5 mg was administered twice a day. Results: PN (grade ≥2) was noted in 32 (39.0%) patients. The median cumulative dose of docetaxel associated with PN was 675 mg/m2. No factor significantly predicted the occurrence of PN. The prostate-specific antigen progression rate, prostate cancer-specific survival, and overall survival were significantly better with ≥8 cycles of docetaxel than with p < 0.05). Conclusion: The incidence of PN is high, and 8 treatment cycles are optimal for patients receiving docetaxel for CRPC.Keywords
This publication has 19 references indexed in Scilit:
- Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivorsEuropean Journal of Cancer, 2015
- Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trialThe Lancet Oncology, 2013
- Chemotherapy-induced peripheral neurotoxicity (CIPN): An updateCritical Reviews in Oncology/Hematology, 2012
- Evaluating the Value of Number of Cycles of Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate CancerEuropean Urology, 2012
- Phase III Trial Comparing Vinflunine With Docetaxel in Second-Line Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing ChemotherapyJournal of Clinical Oncology, 2010
- Docetaxel Plus Prednisolone for the Treatment of Metastatic Hormone-refractory Prostate Cancer: A Multicenter Phase II Trial in JapanJapanese Journal of Clinical Oncology, 2008
- Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working GroupJournal of Clinical Oncology, 2008
- Peripheral Neuropathy Induced by Microtubule-Stabilizing AgentsJournal of Clinical Oncology, 2006
- Phase III Randomized Trial of Docetaxel-Carboplatin Versus Paclitaxel-Carboplatin as First-line Chemotherapy for Ovarian CarcinomaJNCI Journal of the National Cancer Institute, 2004
- Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate CancerThe New England Journal of Medicine, 2004